Legal and Decriminalized Psychedelics

July 9, 2024 Lynne Nardizzi

Here’s an informative article on navigating the legal landscape of psychedelics.

Risks of Psychedelics

July 6, 2024 Lynne Nardizzi

Here’s a great article on the tendency to deny and downplay the harms of psychedelics.

UC Berkeley’s Groundbreaking Study on Psilocybin

July 5, 2024 Lynne Nardizzi

The UC Berkeley Center for the Science of Psychedelics has embarked on an unprecedented study to explore why psilocybin, a psychoactive compound found in certain mushrooms, alters visual perception in humans.

This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use.

Psilocybin, commonly known as “shrooms” or “magic mushrooms,” can significantly distort users’ sense of time, mood, and reality, often causing hallucinations.

Psychedelics for Long-COVID Symptoms?

June 17, 2024 Lynne Nardizzi

A recent case study has highlighted the potential of using MDMA and psilocybin to manage these persistent symptoms.

Cluster Headaches and Psychedelics

June 16, 2024 Lynne Nardizzi

Here’s a wonderful article on how people with cluster headaches became unexpected psychedelic pioneers.

Trauma and Challenging Trips

June 15, 2024 Lynne Nardizzi

A recent study has challenged the prevailing belief that childhood trauma influences the experiences individuals have with ayahuasca, a psychoactive brew traditionally used by Indigenous cultures for spiritual and healing purposes.

Oprah Has a User's Guide for Psychedelics

June 14, 2024 Lynne Nardizzi

Oprah’s website OprahDaily.com has published a guide to psychedelics and psychedelic-assisted therapy.

Psilocybin for Anorexia

June 6, 2024 Lynne Nardizzi

A recent study has shed light on the potential of psilocybin, the active compound in magic mushrooms, as a promising treatment for anorexia nervosa (AN).

This psychiatric disorder, known for its high mortality rate, has long been a challenging condition to treat effectively.

The research, conducted at Monash University, revealed that psilocybin could improve cognitive flexibility and help maintain body weight in an animal model of AN.

Psychedelics and Prolonged Grief Disorder

June 3, 2024 Lynne Nardizzi

Psychedelics such as psilocybin and MDMA may be a promising treatment avenue for Prolonged Grief Disorder (PGD).

Randomized clinical trials demonstrated the efficacy of psilocybin in reducing symptom severity in depression and MDMA in reducing PTSD symptomatology.

Furthermore, psychedelics often produce subjective effects (such as transcendence, mystical experiences, and a sense of oneness) that may be uniquely relevant to the existential distress experienced in PGD.

Study: Psychedelics and the Inner Healer

May 21, 2024 Lynne Nardizzi

Reference to an intrinsic healing mechanism or an ‘inner healer’ is commonplace amongst psychedelic users.

Inner healer scores were higher after the high versus placebo dose of psilocybin. Within the high-dose sub-sample only, inner healer scores predicted improved depressive symptomatology at 2 weeks post-dosing.

Psychological Flexibility and Psychedelics

April 29, 2024 Lynne Nardizzi

In a new study, researchers found that psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved following psilocybin and were maintained through week 16.

Additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin.

Keep reading for the full article at Nature.com

Blog